Latest news with #JeneneThomas
Associated Press
14-05-2025
- Business
- Associated Press
Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event
Live webcast followed by an interactive Q&A session on Thursday, May 22ndat 4:00 PM ET Access the eventhere THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company's first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed. The live video webcast will be available on the Events page under the Investors section of the Company's website ( ). A webcast replay will be available two hours following the live event and will be accessible for 90 days. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media Contact JTC Team, LLC Jenene Thomas (908) 824-0775 [email protected]
Associated Press
01-05-2025
- Business
- Associated Press
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means' Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase ('POC 1') where clinically meaningful pain reduction was demonstrated Outlines Company's plans to initiate market expansion study ('POC 2') into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the 'What This Means' video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor 'What This Means' segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's successfully met initial phase of the first-in-human proof-of-concept trial ('PoC 1') and the advancement to a follow-on phase ('PoC 2') evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The 'What This Means' video can be accessed here. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media Contact JTC Team, LLC Jenene Thomas 908.824.0775 [email protected]
Associated Press
10-03-2025
- Business
- Associated Press
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ('TuHURA'), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat on Tuesday, March 18, 2025 at 8:30 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA. In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website. live webcast of the fireside chat will be available on the Events page of the Investors section of the Company's website ( About TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. TuHURA's lead innate immune agonist drug candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate in second quarter 2025, a single randomized placebo-controlled Phase 3 registration=directed trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® and placebo in first=line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune agonist candidates, following the closing of the previously announced proposed merger with Kineta, TuHURA plans to advance its VISTA inhibiting antibody into a phase two trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML. Leveraging its discovery of the central role the Delta Opioid Receptor plays in modulating the immunosuppressive effects of myeloid derived suppressor cells (MDSCs) and tumor associated M2 polarized macrophages on the tumor microenvironment (TME), the Company is also developing non-tumor targeting ADCs and APCs to convert the TME to an immunogenic phenotype, potentially overcoming acquired resistance to checkpoint inhibitors and cellular therapies. Investor Contact: JTC Team, LLC Jenene Thomas
Associated Press
14-02-2025
- Business
- Associated Press
JTC Team to Host the Virtual Investor 'Top 5 for '25" On-Demand Conference
- Video webcasts to be available on-demand Wednesday, February 19th - Participating company line-up to be announced - Top 5 for '25 promo video can be accessed here FRENCHTOWN, NJ / ACCESS Newswire JTC Team ('JTC'), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 'Top 5 for '25" Conference with on-demand presentations available beginning Wednesday, February 19, 2025. For the event, management from the participating companies will provide their top five reasons of why they believe the investment community and industry colleagues should pay attention to their company in 2025. All investors and interested parties will be able to access the list of participating companies at The on-demand presentations will be available on the Virtual Investor website, as well as the Investor sections of the respective company websites. To access all Virtual Investor events, visit JTC Team and Virtual Investor Co. are paid consultants to the participating companies. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of the applicable companies. Interested parties are responsible for conducting their own due diligence and are encouraged to review the companies' websites and the SEC website for the latest information and filings on each company. About JTC Team JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit or connect with the company on X and LinkedIn. Contact: Jenene Thomas JTC Team, LLC
Associated Press
29-01-2025
- Business
- Associated Press
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade', 'Palisade Bio', or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn's & Colitis Congress being held February 6-8, 2025 in San Francisco, CA. Details of the poster presentation are as follows: Session: Poster and Exhibition Hall Reception Poster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PST Presentation Location: Level 1 – Exhibition Hall – Moscone West For more information about the congress, please visit About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to Jenene Thomas 908-824-0775
